autologous hematopoietic stem cells transduced with CCR5shRNA, HIV-1 pol and vpu miRNA, and CCR5delta32 (University of Florida/Vectorite Biomedica)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameautologous hematopoietic stem cells transduced with CCR5shRNA, HIV-1 pol and vpu miRNA, and CCR5delta32 (University of Florida/Vectorite Biomedica)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionC-C chemokine receptor type 5 antagonists

TargetsC-C chemokine receptor type 5

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwan

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Florida

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesVectorite Biomedica Inc University Of Florida

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A